Anti Nuclear Antibody (ANA) - IFA

A positive ANA by IFA means your blood contains antinuclear antibodies—proteins that may target cell nuclei. It can suggest an autoimmune disease (e.g., lupus, Sjögren’s, scleroderma) but also appears in healthy people, infections, certain drugs, or with aging. The titer and staining pattern, symptoms, and specific antibody tests determine significance. Discuss results and next steps with your clinician.

An anti‑nuclear antibody (ANA) by IFA is an autoantibody test performed by indirect immunofluorescence using cultured cells (commonly HEp‑2) to detect antibodies that bind nuclear components. Fluorescent staining patterns (homogeneous, speckled, nucleolar, centromere) and titres help indicate autoimmune conditions such as systemic lupus erythematosus or scleroderma, but a positive result alone does not confirm disease and requires clinical correlation.

Antinuclear antibodies can be positive in various cancers, especially hematologic malignancies (non‑Hodgkin lymphoma, chronic lymphocytic leukemia and other leukemias) and some solid tumors—particularly breast, lung (including small‑cell), ovarian, gastrointestinal, liver and renal cancers. Thymoma is also associated. ANA in cancer often reflects paraneoplastic autoimmunity and is nonspecific, requiring clinical correlation.

The IFA (indirect immunofluorescence assay) detects specific antibodies or antigens in blood or tissue using fluorescent‑labelled antibodies. Clinically it helps diagnose infections (viral, bacterial, parasitic), identify autoimmune antibodies and patterns (for example ANA), and confirm serological responses. Results support diagnosis, monitor immune response, or guide further testing for infectious or autoimmune conditions.

Not necessarily — a positive ANA is common and can occur in healthy people, older adults, infections or medication exposure. Significance depends on titer, pattern and your symptoms. High titers or symptoms suggesting autoimmune disease (joint pain, rash, Raynaud’s, unexplained fatigue/fever) warrant further blood tests and rheumatology assessment. Discuss results with your clinician to decide next steps.

No single blood test definitively confirms systemic lupus erythematosus (SLE). ANA (antinuclear antibody) is a sensitive screening test; positive results prompt specific antibody testing. Anti–double‑stranded DNA (anti-dsDNA) and anti‑Smith antibodies are more specific and can support diagnosis, with anti‑dsDNA often correlating with disease activity. Complement levels (C3/C4), CBC, inflammatory markers, and urinalysis assess activity and organ involvement.